Lloyd Price
FEBRUARY 13, 2024
The biotech company is a spin-out of the University of Dundee and develops targeted protein degradation medicines, which have the potential to treat serious diseases that currently have limited treatments. These initiatives are helping to create a supportive environment for healthtech companies to thrive. "At
Insulin Nation
APRIL 4, 2014
It was enough for some biotech investment columnists to preemptively write Mannkind’s obituary. Marketed by Pfizer in 2006, Exubera was supposed to bring in $2 billion a year in sales. Instead, with the vote, Afrezza lives to fight another day. billion loss on it.
Digital Health Global
NOVEMBER 20, 2023
Drawing on AstraZeneca’s deep experience of developing novel therapeutics and with insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech and CROs to support clinical research globally. 2 Digital health is a large (+$900bn by 2032) and growing (13.6%
Expert insights. Personalized for you.
64 
Let's personalize your content